Encapsulating peritoneal sclerosis

Last updated
Encapsulating peritoneal sclerosis
Specialty Gastroenterology

Encapsulating peritoneal sclerosis(EPS) also known as sclerosing encapsulating peritonitis, is a rare but serious complication of long-term peritoneal dialysis in which progressive fibrotic thickening of the peritoneum can partially or completely encase the bowel, leading to recurrent or persistent bowel obstruction and malnutrition. [1]

Contents

Terminology

Terminology for this condition varies by specialty and etiology. Not to be confused with congenital peritoneal encapsulation, a rare developmental anomaly in which a thin accessory peritoneal membrane encloses all or part of the small bowel. [2] . In nephrology, encapsulating peritoneal sclerosis is commonly used for the form associated with long-term peritoneal dialysis. [1] In surgical and radiology literature, abdominal cocoon is often used for idiopathic cases of sclerosing encapsulating peritonitis, although terminology is inconsistent across publications. [3]

Signs and symptoms

Patients usually present with abdominal symptoms such as altered bowel habits, nausea, vomiting, anorexia, and early satiety. [4] In the early stages, these symptoms can be linked to signs of inflammation such as pyrexia and elevated CRP, and/or blood-stained ascites. [5]

Abdominal pain, fullness, overt bowel obstruction, and the presence of an abdominal mass are linked to the late stages of encapsulating peritoneal sclerosis. The intestines become gradually covered with a fibrous cocoon, which causes weight loss, malnutrition, bowel obstruction, ischemia and strangulation, infection, and death. [6]

Causes

Encapsulating peritoneal sclerosis is typically observed in patients with end-stage renal disease (ESRD) receiving long-term peritoneal dialysis therapy. Dialysis fluid's high glucose content and acidic pH cause harm to the peritoneum. [7] High glucose concentrations promote osmosis and diffusion gradients across the peritoneum, while low pH inhibits the production of harmful glucose degradation products (GDPs). [8] GDPs are created when peritoneal dialysis fluid is heated to sterilize it [9] and these result in the production of advanced glycation end products (AGEs) when glucose is present. [10] Less GDP-containing biocompatible solutions are now more frequently used, which lessens peritoneal damage. [11]

Encapsulating peritoneal sclerosis can also occur in patients who are not on peritoneal dialysis but are suffering from other illnesses like endometriosis, sarcoidosis, peritoneal and intra-abdominal cancers, chronic peritoneal ascites, intraperitoneal chemotherapy, intraperitoneal exposure to particulate matter or disinfectant, abdominal surgery, intraperitoneal infections (tuberculosis), and beta-blocker administration. [12] [13]

Risk factors

The length of peritoneal dialysis treatment appears to be the primary risk factor for encapsulating peritoneal sclerosis development. The incidence of encapsulating peritoneal sclerosis rose with the length of peritoneal dialysis (PD) in an Australian survey; for patients on PD for more than 2, 5, 6, and 8 years, the rates were 1.9, 6.4, 10.8, and 19.4%, respectively. [14]

Given that there is a high incidence of encapsulating peritoneal sclerosis shortly after renal transplantation, organ transplantation seems to increase the risk of developing this condition. [15]

A frequent side effect of peritoneal dialysis, peritonitis is intricately linked to the development of encapsulating peritoneal sclerosis, with the frequency of episodes being correlated with the occurrence of encapsulating peritoneal sclerosis. [16] Encapsulating peritoneal sclerosis has been specifically linked to recurrent peritonitis caused by bacterial contamination, [17] specifically from Pseudomonas spp., Staphylococcus aureus, and specific fungal [18] organisms. [14]

Triggers

Implicated triggers include systemic rheumatologic and inflammatory disorders, [19] [20] dermoid cyst rupture, [21] gynecologic neoplasms, [22] [23] endometriosis, [24] organ transplantation, [25] [26] [27] cirrhosis, [28] mechanical or chemical intraperitoneal irritants, [29] [30] [31] infection, [32] [33] and medications. [34] [35]

Mechanism

Encapsulating peritoneal sclerosis is believed to happen in patients who have a predisposing condition if a peritoneal inflammatory process (inciting factor) takes place. This is known as the "two-hit" theory in the literature on peritoneal dialysis, according to which the non-inflammatory peritoneal sclerosis brought on by repeated dialysis treatments is the "first hit" or predisposing factor. [36] This is corroborated by the fact that during peritoneal dialysis, the cumulative incidence of encapsulating peritoneal sclerosis rises significantly over time. [37] A proinflammatory "second hit" [38] initiates a series of proangiogenic [ vascular endothelial growth factor (VEGF)], proinflammatory [ transforming growth factor β1 (TGFβ1), interleukin-6 (IL-6), CCN2] cytokines. [39] [40] TGFβ1 stimulates peritoneal mesothelial cells to transdifferentiate into mesenchymal cells, which leads to the depletion of mesothelial cells, [41] [42] increased extracellular matrix component production [ collagen type 1, alpha 1 (COL1A1)], and fibrogenesis, which forms a fibrocollagenous cocoon. [43]

Diagnosis

Encapsulating peritoneal sclerosis is diagnosed clinically, supported by radiography or laparotomy, and based on a constellation of clinical findings. [4]

The non-specific laboratory results associated with encapsulating peritoneal sclerosis are linked to underlying infections, malnourishment, and inflammation. [44] [36] It has been demonstrated that dialysate from patients with encapsulating peritoneal sclerosis had higher levels of inflammatory cytokines than did peritoneal dialysis controls, sometimes up to years before the condition's clinical manifestation. [45] [46] Nevertheless, no biomarker has been discovered to help anticipate the onset of encapsulating peritoneal sclerosis. [47]

When distinguishing encapsulating peritoneal sclerosis from other causes of intestinal obstruction, imaging is frequently useful. Advanced encapsulating peritoneal sclerosis may be suggested by abdominal plain films with peritoneal calcification and dilated bowel loops with air-fluid levels. [4] The small bowel follow-through may be characterized by delayed transit, distension near small bowel adhesions, and a "cauliflower" appearance due to peritoneal sclerosis-encapsulated bowel loop compression. Dilated loops of bowel may appear encased in a dense fibrous membrane or matted together and tethered posteriorly on ultrasonography. [48] The appearance of a trilaminar colon wall may be due to intraperitoneal echogenic strands. [49]

As of right now, the most extensively researched and widely used imaging method for encapsulating peritoneal sclerosis diagnosis is the CT scan. Small bowel loops are frequently connected by a thickened, encircling peritoneum, which is usually accompanied by proximal bowel dilatation. [49] Increased mesenteric fat density, loculated ascites, and localized or diffuse peritoneal calcification are additional radiographic features. [50] [4] Complex loculations may indicate intra-abdominal hemorrhage, but if they contain gas, there is reason to suspect sepsis or a perforation. [51] Elevated thickening or enhancement of the colon wall suggests transmural fibrosis or persistent inflammation. [49] Although it hasn't been used as much for diagnosis, magnetic resonance imaging probably produces similar results. Benefits include better bowel encasement and peritoneal thickening delineation, as well as the avoidance of ionizing radiation. [52]

The histologic results for encapsulating peritoneal sclerosis are not specific and can be confused with those for infectious peritonitis or simple peritoneal sclerosis. [53] The mesothelial cell layer is microscopically denuded by fibrin deposition, fibroblast proliferation, and fibrocollagenous deposition. When inflammation is active, there may be an infiltration of inflammatory mononuclear cells. [38] Encapsulating peritoneal sclerosis is distinguished from peritoneal sclerosis and peritonitis by the transmembrane glycoprotein podoplanin, which is present on peritoneal mesothelial cells and binds inflammatory cytokines. [54]

Classification

Based on the clinical presentation, encapsulating peritoneal sclerosis is classified into four stages: [4]

  1. Pre-encapsulating peritoneal sclerosis stage: Mild ascites, no inflammation, and no symptoms. [4]
  2. Inflammatory stage: The patient's symptoms, which include intestinal swelling and partial encapsulation of the bowel, nausea and diarrhea. There is an exudation of fibrin and mild inflammation. [4]
  3. Encapsulation: Signs of intestinal blockage brought on by the encapsulation-causing fibrous cocoon. It may be linked to inflammation, ranging from mild to severe. [4]
  4. Chronic stage of ileus: The thickening of the encapsulating fibrous cocoon causes patients to experience complete bowel obstruction. At this point, there's not much, if any, inflammation. [4]

Prevention

There is currently no known way to stop encapsulating peritoneal sclerosis from developing, despite numerous studies pointing to potential causes. There has been much discussion regarding the "expiry date" for patients receiving peritoneal dialysis because the risk of developing encapsulating peritoneal sclerosis rises with the length of the treatment. [7] Research from Japan has indicated that patients should switch to hemodialysis after the recommended 8-year safe period for continuing peritoneal dialysis. [55] Setting an expiration date, however, is not advised since it may worsen quality of life and raise the risk of complications for patients receiving hemodialysis via tunneled lines in cases where they had no symptoms while receiving peritoneal dialysis. [56]

Treatment

Treating the underlying cause of encapsulating peritoneal sclerosis is recommended whenever it is feasible. This entails switching from peritoneal dialysis to hemodialysis in the case of peritoneal dialysis. [7]

The nutritional status should be evaluated upon encapsulating peritoneal sclerosis diagnosis. Encapsulating peritoneal sclerosis cannot be effectively treated with bowel rest or total parenteral nutrition (TPN) alone; however, making sure the patient receives enough nutrition is crucial. [55] Enteral feeding is frequently not tolerated due to obstruction, necessitating TPN. [57]

Many medications have been used to target the inflammatory component of encapsulating peritoneal sclerosis such as mammalian target of rapamycin (mTOR) inhibitors, [58] cyclosporine, [59] mycophenolate mofetil, [60] colchicine, [61] corticosteroids, and azathioprine. [13] [62]

For patients who have already experienced significant fibrosis, immunosuppression might not be enough. A potent anti-fibrotic agent, tamoxifen is a selective estrogen receptor modulator (SERM) that inhibits TGF-β, a crucial cytokine in the fibrosis process. [63]

Because encapsulating peritoneal sclerosis surgery is a time-consuming, dangerous, and technical procedure, it should only be performed on patients who have not responded to conservative medical therapy and, if at all possible, in facilities with prior experience performing such procedures. [64] [65]

Outlook

Patients with encapsulating peritoneal sclerosis have a very high death rate, which ranges from 26% to 58%, and rises with the length of peritoneal dialysis. [15] [66] Malnutrition and sepsis are the most common causes of death among those with encapsulating peritoneal sclerosis. [67]

Epidemiology

Encapsulating peritoneal sclerosis occurs between 0.5% and 7.3% of the time worldwide, but in patients receiving peritoneal dialysis for 15 years or longer, the frequency can reach 17.2%. [37] After nine years of peritoneal dialysis, the encapsulating peritoneal sclerosis risk rose to 8% in one study involving over 17,300 patients from Australia, New Zealand, and Scotland; however, when the competing risk of death was considered, the risk dropped to just 1.5%. [68]

See also

References

Creative Commons by small.svg  This article incorporates text available under the CC BY 4.0 license.

  1. 1 2 Korte, M.R.; Sampimon, D.E.; Betjes, M.G.H.; Krediet, R.T. (2011). "Encapsulating peritoneal sclerosis: the state of affairs". Nature Reviews Nephrology. 7 (9): 528–538. doi:10.1038/nrneph.2011.93. PMID   21808281.
  2. ↑ Dave, A; et al. (2019). "Congenital peritoneal encapsulation: A review and novel classification system". World Journal of Gastroenterology. 25 (19): 2294–2307. doi: 10.3748/wjg.v25.i19.2294 . PMC   6529893 . PMID   31148901.
  3. ↑ Singhal, M.; et al. (2019). "Encapsulating Peritoneal Sclerosis: The Abdominal Cocoon". Radiographics. 39 (1): 62–77. doi:10.1148/rg.2019180108. PMID   30526331.
  4. 1 2 3 4 5 6 7 8 9 Nakamoto, Hidetomo (April 2005). "Encapsulating peritoneal sclerosis--a clinician's approach to diagnosis and medical treatment". Peritoneal Dialysis International. 25 (4): S30 –S38. doi:10.1177/089686080502504S05. PMID   16300270. S2CID   18937047.
  5. ↑ Maruyama, Yukio; Nakayama, Masaaki (June 2008). "Encapsulating peritoneal sclerosis in Japan". Peritoneal Dialysis International. 28 (3): S201 –S204. doi:10.1177/089686080802803s37. PMID   18552256. S2CID   45478695.
  6. ↑ Kawaguchi, Y; Kawanishi, H; Mujais, S; Topley, N; Oreopoulos, D G (2000). "Encapsulating peritoneal sclerosis: definition, etiology, diagnosis, and treatment. International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis". Peritoneal Dialysis International. 20 (4): S43 –S55. doi:10.1177/089686080002004S04. PMID   11098928.
  7. 1 2 3 Moinuddin, Zia; Summers, Angela; Van Dellen, David; Augustine, Titus; Herrick, Sarah E. (January 5, 2015). "Encapsulating peritoneal sclerosisâ€"a rare but devastating peritoneal disease". Frontiers in Physiology. 5. Frontiers Media SA: 470. doi: 10.3389/fphys.2014.00470 . ISSN   1664-042X. PMC   4283512 . PMID   25601836.
  8. ↑ Jörres, A; Topley, N; Gahl, G M (February 1992). "Biocompatibility of peritoneal dialysis fluids". The International Journal of Artificial Organs. 15 (2): 79–83. doi:10.1177/039139889201500203. PMID   1555880.
  9. ↑ Wieslander, A P (June 1996). "Cytotoxicity of peritoneal dialysis fluid — is it related to glucose breakdown products?". Nephrology, Dialysis, Transplantation. 11 (6): 958–959. PMID   8671949.
  10. ↑ Mortier, Siska; De Vriese, An S.; Van de Voorde, Johan; Schaub, Thomas P.; Passlick-Deetjen, Jutta; Lameire, Norbert H. (2002). "Hemodynamic Effects of Peritoneal Dialysis Solutions on the Rat Peritoneal Membrane". Journal of the American Society of Nephrology. 13 (2). Ovid Technologies (Wolters Kluwer Health): 480–489. doi:10.1681/asn.v132480. ISSN   1046-6673. PMID   11805178.
  11. ↑ Boulange, Eric (2008). "Peritoneal and systemic inflammation: the benefits of using biocompatible peritoneal dialysis fluids". Peritoneal Dialysis International. 28 (1): 28–31. doi:10.1177/089686080802800106. PMID   18178944.
  12. ↑ Pollock, C A (2001). "Diagnosis and management of encapsulating peritoneal sclerosis". Peritoneal Dialysis International. 21 (3): S61 –S66. doi:10.1177/089686080102103S10. PMID   11887865.
  13. 1 2 Kawanishi, Hideki; Moriishi, Misaki (April 2005). "Epidemiology of encapsulating peritoneal sclerosis in Japan". Peritoneal Dialysis International. 25 (4): S14 –S18. PMID   16300268.
  14. 1 2 Rigby, R. J.; Hawley, C. M. (January 1, 1998). "Sclerosing peritonitis: the experience in Australia". Nephrology Dialysis Transplantation. 13 (1). Oxford University Press (OUP): 154–159. doi:10.1093/ndt/13.1.154. ISSN   0931-0509. PMID   9481732.
  15. 1 2 Balasubramaniam, Gowrie; Brown, Edwina A.; Davenport, Andrew; Cairns, Hugh; Cooper, Barbara; Fan, Stanley L. S.; Farrington, Ken; Gallagher, Hugh; Harnett, Patrick; Krausze, Sally; Steddon, Simon (February 11, 2009). "The Pan-Thames EPS study: treatment and outcomes of encapsulating peritoneal sclerosis". Nephrology Dialysis Transplantation. 24 (10). Oxford University Press (OUP): 3209–3215. doi:10.1093/ndt/gfp008. ISSN   1460-2385. PMID   19211652.
  16. ↑ Yamamoto, Ryo; Otsuka, Yasushi; Nakayama, Masaaki; Maruyama, Yukio; Katoh, Naohiko; Ikeda, Masato; Yamamoto, Hiroyasu; Yokoyama, Keitaro; Kawaguchi, Yoshindo; Matsushima, Masato (June 24, 2005). "Risk factors for encapsulating peritoneal sclerosis in patients who have experienced peritoneal dialysis treatment". Clinical and Experimental Nephrology. 9 (2). Springer Science and Business Media LLC: 148–152. doi:10.1007/s10157-005-0349-8. ISSN   1342-1751. PMID   15980950. S2CID   26144928.
  17. ↑ Chew, C. G.; Clarkson, A. R.; Faull, R. J. (April 1, 1997). "Relapsing CAPD peritonitis with rapid peritoneal sclerosis due to Haemophilus influenzae". Nephrology Dialysis Transplantation. 12 (4). Oxford University Press (OUP): 821–822. doi:10.1093/ndt/12.4.821. ISSN   0931-0509. PMID   9141024.
  18. ↑ Flanigan, Michael; Anderson, Dale; Freeman, Richard M. (1984). "Peritoneal dialysis complicated by fungal peritonitis and peritoneal fibrosis". The American Journal of Medicine. 76 (5). Elsevier BV: A113. doi:10.1016/0002-9343(84)91017-9. ISSN   0002-9343. PMID   6720720.
  19. ↑ Ngô, Yann; Messing, Bernard; Marteau, Philippe; Nouël, Olivier; Pasquiou, Alain; Lavergne, Anne; Rambaud, Jean Claude (1992). "Peritoneal sarcoidosis". Digestive Diseases and Sciences. 37 (11). Springer Science and Business Media LLC: 1776–1780. doi:10.1007/bf01299875. ISSN   0163-2116. PMID   1425080. S2CID   28350203.
  20. ↑ Dabak, Resat (2005). "Encapsulating peritonitis and familial Mediterranean fever". World Journal of Gastroenterology. 11 (18). Baishideng Publishing Group Inc.: 2844–2846. doi: 10.3748/wjg.v11.i18.2844 . ISSN   1007-9327. PMC   4305931 . PMID   15884137.
  21. ↑ Fossey, SJ; Simson, JNL (2011). "Sclerosing encapsulating peritonitis secondary to dermoid cyst rupture: a case report". The Annals of the Royal College of Surgeons of England. 93 (5). Royal College of Surgeons of England: e39 –e40. doi:10.1308/147870811x582495. ISSN   0035-8843. PMC   5827212 . PMID   21943446.
  22. ↑ Bahar, Burak; Hu, Zhihong; Szpaderska, Anna; Liotta, Margaret; Potkul, Ronald K.; Smith, Donna; Erşahin, Çağatay (2014). "Fatal Case of Luteinized Thecoma With Sclerosing Peritonitis in a 40-Year-Old Woman". International Journal of Gynecological Pathology. 33 (1). Ovid Technologies (Wolters Kluwer Health): 30–34. doi:10.1097/pgp.0b013e31827d1a65. ISSN   0277-1691. PMID   24300532. S2CID   27140004.
  23. ↑ Walker, Jane; Moss, Esther L.; Ganesan, Raji; Hirschowitz, Lynn (2012). "Sclerosing Peritonitis Associated With a Luteinized Adult Granulosa Cell Tumor". International Journal of Gynecological Pathology. 31 (2). Ovid Technologies (Wolters Kluwer Health): 141–144. doi:10.1097/pgp.0b013e3182307b28. ISSN   0277-1691. PMID   22317869.
  24. ↑ Frigerio, Luigi; Taccagni, Gian Luca; Mariani, Andrea; Mangili, Giorgia; Ferrari, Augusto (1997). "Idiopathic sclerosing peritonitis associated with florid mesothelial hyperplasia, ovarian fibromatosis, and endometriosis: A new disorder of abdominal mass". American Journal of Obstetrics and Gynecology. 176 (3). Elsevier BV: 721–722. doi:10.1016/s0002-9378(97)70581-7. ISSN   0002-9378. PMID   9077640.
  25. ↑ Lee, Kyo Won; Cho, Chan Woo; Lee, Nuri; Lee, Sanghoon; Kim, Jong Man; Choi, Gyu-Seong; Kwon, Choon Hyuck David; Joh, Jae-Won; Lee, Suk-Koo (2017). "Encapsulating peritoneal sclerosis in liver transplant recipients: a report of 2 cases". Annals of Surgical Treatment and Research. 92 (3). The Korean Surgical Society: 164–167. doi:10.4174/astr.2017.92.3.164. ISSN   2288-6575. PMC   5344807 . PMID   28289671.
  26. ↑ Morrow, Ellen H.; Gallo, Amy E.; Melcher, Marc L. (November 10, 2010). "Sclerosing Peritonitis After Kidney Transplantation: A Not-So-Silky Cocoon". Digestive Diseases and Sciences. 56 (2). Springer Science and Business Media LLC: 307–310. doi:10.1007/s10620-010-1471-3. ISSN   0163-2116. PMID   21063775. S2CID   22601942.
  27. ↑ Rumbo, Carolina; Zambernardi, Agustina; Cabanne, Ana; Rumbo, Martin; Gondolesi, Gabriel (July 3, 2013). "Sclerosing peritonitis, a rare complication after intestinal transplant. Report of one case successfully treated with adjustment of immunosuppression". Pediatric Transplantation. 17 (5). Wiley: E125-9. doi:10.1111/petr.12110. hdl: 11336/23404 . ISSN   1397-3142. PMID   23902605. S2CID   21314087.
  28. ↑ Wakabayashi, Hisao; Okano, Keiichi; Suzuki, Yasuyuki (2007). "Clinical Challenges and Images in GI". Gastroenterology. 132 (3). Elsevier BV: 854–1210. doi:10.1053/j.gastro.2007.01.060. ISSN   0016-5085. PMID   17383416.
  29. ↑ Takebayashi, Katsushi; Sonoda, Hiromichi; Shimizu, Tomoharu; Ohta, Hiroyuki; Ishida, Mitsuaki; Mekata, Eiji; Endo, Yoshihiro; Tani, Tohru; Tani, Masaji (August 27, 2014). "Successful surgical approach for a patient with encapsulating peritoneal sclerosis after hyperthermic intraperitoneal chemotherapy: a case report and literature review". BMC Surgery. 14 (1). Springer Science and Business Media LLC: 57. doi: 10.1186/1471-2482-14-57 . ISSN   1471-2482. PMC   4149037 . PMID   25160862.
  30. ↑ Sigaroudinia, Mandana O.; Baillie, Colin; Ahmed, Shiban; Mallucci, Connor (2008). "Sclerosing encapsulating peritonitis—a rare complication of ventriculoperitoneal shunts". Journal of Pediatric Surgery. 43 (5). Elsevier BV: e31 –e33. doi:10.1016/j.jpedsurg.2008.01.019. ISSN   0022-3468. PMID   18485933.
  31. ↑ Arnadottir, M.; Jonasson, J. G.; Indridason, O. S. (February 11, 2011). "Encapsulating peritoneal sclerosis following a peritoneal foreign body reaction to Dacron fibres--a case report". Clinical Kidney Journal. 4 (2). Oxford University Press (OUP): 107–109. doi:10.1093/ndtplus/sfq202. ISSN   2048-8505. PMC   4421583 . PMID   25984126.
  32. ↑ Hsu, Yung-Hsuen; Hsia, Ching-Chih; Tsai, Dong-Ming; Tu, Hsing-Yang; Hung, Kuan-Yu; Huang, Jenq-Wen (2010). "Development of Encapsulating Peritoneal Sclerosis Following Bacterial Peritonitis in a Peritoneal Dialysis Patient". American Journal of Kidney Diseases. 55 (1). Elsevier BV: 198–202. doi:10.1053/j.ajkd.2009.06.043. ISSN   0272-6386. PMID   19782452.
  33. ↑ Tan, J.; Manickam, R.; Pisharam, J.; Telisinghe, P.; Chong, V.H. (2012). "Mucormycosis—A Possible Trigger Pathogen for Encapsulating Peritoneal Sclerosis". Peritoneal Dialysis International. 32 (4). SAGE Publications: 479–481. doi:10.3747/pdi.2011.00241. ISSN   0896-8608. PMC   3524856 . PMID   22859845.
  34. ↑ Eltringham, W K; Espiner, H J; Windsor, C W O; Griffiths, D A; Davies, J D; Baddeley, H; Read, A E A; Blunt, R J (1977). "Sclerosing peritonitis due to practolol: A report on 9 cases and their surgical management". British Journal of Surgery. 64 (4). Oxford University Press (OUP): 229–235. doi:10.1002/bjs.1800640402. ISSN   0007-1323. PMID   856375. S2CID   33419488.
  35. ↑ Nauen, David W.; Martin, Allison; Katz, Aviva; Cohen, Debra; Ranganathan, Sarangarajan (October 21, 2009). "A case of luteinizing thecoma with sclerosing peritonitis: Revisiting a link with anti-epileptic drugs". Pediatric Blood & Cancer. 54 (3). Wiley: 470–472. doi:10.1002/pbc.22325. ISSN   1545-5009. PMID   19847882. S2CID   20286106.
  36. 1 2 Alston, Helen; Fan, Stanley; Nakayama, Masaaki (2017). "Encapsulating Peritoneal Sclerosis". Seminars in Nephrology. 37 (1). Elsevier BV: 93–102. doi:10.1016/j.semnephrol.2016.10.010. ISSN   0270-9295. PMID   28153198.
  37. 1 2 Johnson, David W.; Cho, Yeoungjee; Livingston, Brian E.R.; Hawley, Carmel M.; McDonald, Stephen P.; Brown, Fiona G.; Rosman, Johan B.; Bannister, Kym M.; Wiggins, Kathryn J. (2010). "Encapsulating peritoneal sclerosis: incidence, predictors, and outcomes". Kidney International. 77 (10). Elsevier BV: 904–912. doi: 10.1038/ki.2010.16 . ISSN   0085-2538. PMID   20375981.
  38. 1 2 Honda, Kazuho; Oda, Hideaki (April 2005). "Pathology of encapsulating peritoneal sclerosis". Peritoneal Dialysis International. 25 (4): S19 –S29. doi:10.1177/089686080502504S04. PMID   16300269. S2CID   10389752.
  39. ↑ Abrahams, Alferso C.; Habib, Sayed M.; Dendooven, Amélie; Riser, Bruce L.; van der Veer, Jan Willem; Toorop, Raechel J.; Betjes, Michiel G. H.; Verhaar, Marianne C.; Watson, Christopher J. E.; Nguyen, Tri Q.; Boer, Walther H. (November 10, 2014). "Patients with Encapsulating Peritoneal Sclerosis Have Increased Peritoneal Expression of Connective Tissue Growth Factor (CCN2), Transforming Growth Factor-β1, and Vascular Endothelial Growth Factor". PLOS ONE. 9 (11) e112050. Public Library of Science (PLoS). Bibcode:2014PLoSO...9k2050A. doi: 10.1371/journal.pone.0112050 . ISSN   1932-6203. PMC   4226475 . PMID   25384022.
  40. ↑ Lambie, Mark R.; Chess, James; Summers, Angela M.; Williams, Paul Ford; Topley, Nicholas; Davies, Simon J. (January 26, 2016). "Peritoneal inflammation precedes encapsulating peritoneal sclerosis: results from the GLOBAL Fluid Study". Nephrology Dialysis Transplantation. 31 (3). Oxford University Press (OUP): 480–486. doi:10.1093/ndt/gfv440. ISSN   0931-0509. PMID   26908833.
  41. ↑ Braun, N.; Alscher, D. M.; Fritz, P.; Edenhofer, I.; Kimmel, M.; Gaspert, A.; Reimold, F.; Bode-Lesniewska, B.; Ziegler, U.; Biegger, D.; Wuthrich, R. P.; Segerer, S. (August 13, 2010). "Podoplanin-positive cells are a hallmark of encapsulating peritoneal sclerosis". Nephrology Dialysis Transplantation. 26 (3). Oxford University Press (OUP): 1033–1041. doi: 10.1093/ndt/gfq488 . ISSN   0931-0509. PMID   20709739.
  42. ↑ Lopez-Anton, Melisa; Lambie, Mark; Lopez-Cabrera, Manuel; Schmitt, Claus P.; Ruiz-Carpio, Vicente; Bartosova, Maria; Schaefer, Betti; Davies, Simon; Stone, Timothy; Jenkins, Robert; Taylor, Philip R.; Topley, Nicholas; Bowen, Timothy; Fraser, Donald (2017). "miR-21 Promotes Fibrogenesis in Peritoneal Dialysis". The American Journal of Pathology. 187 (7). Elsevier BV: 1537–1550. doi: 10.1016/j.ajpath.2017.03.007 . ISSN   0002-9440. PMID   28495592.
  43. ↑ Reimold, Fabian R.; Braun, Niko; Zsengellér, Zsuzsanna K.; Stillman, Isaac E.; Karumanchi, S. Ananth; Toka, Hakan R.; Latus, Joerg; Fritz, Peter; Biegger, Dagmar; Segerer, Stephan; Alscher, M. Dominik; Bhasin, Manoj K.; Alper, Seth L. (February 13, 2013). "Transcriptional Patterns in Peritoneal Tissue of Encapsulating Peritoneal Sclerosis, a Complication of Chronic Peritoneal Dialysis". PLOS ONE. 8 (2) e56389. Public Library of Science (PLoS). Bibcode:2013PLoSO...856389R. doi: 10.1371/journal.pone.0056389 . ISSN   1932-6203. PMC   3572070 . PMID   23418565.
  44. ↑ Cho, R.; Ghag, D.; Karim, M. A.; Lo, C. (November 11, 2015). "Encapsulating peritoneal sclerosis: surgery, sustained drug therapy and treatment of recurrence at 1 year". BMJ Case Reports. 2015 (nov11 1). BMJ: bcr2015211490. doi:10.1136/bcr-2015-211490. ISSN   1757-790X. PMC   4654214 . PMID   26561223.
  45. ↑ Lopes Barreto, Deirisa; Struijk, Dirk G.; Krediet, Raymond T. (2015). "Peritoneal Effluent MMP-2 and PAI-1 in Encapsulating Peritoneal Sclerosis". American Journal of Kidney Diseases. 65 (5). Elsevier BV: 748–753. doi:10.1053/j.ajkd.2014.10.022. ISSN   0272-6386. PMID   25530106.
  46. ↑ Ahmad, Sohail; North, Bernard V.; Qureshi, Ashfaq; Malik, Amir; Bhangal, Gurjeet; Tarzi, Ruth M.; Brown, Edwina A.; Tam, Frederick W. K. (November 18, 2010). "CCL18 in peritoneal dialysis patients and encapsulating peritoneal sclerosis". European Journal of Clinical Investigation. 40 (12). Wiley: 1067–1073. doi:10.1111/j.1365-2362.2010.02353.x. ISSN   0014-2972. PMID   20695883. S2CID   24656350.
  47. ↑ Goodlad, Catriona; Tam, Frederick W.K.; Ahmad, Sohail; Bhangal, Gurjeet; North, Bernard V.; Brown, Edwina A. (2014). "Dialysate Cytokine Levels do not Predict Encapsulating Peritoneal Sclerosis". Peritoneal Dialysis International. 34 (6). SAGE Publications: 594–604. doi:10.3747/pdi.2012.00305. ISSN   0896-8608. PMC   4164403 . PMID   24584593.
  48. ↑ Akbulut, Sami (2015). "Accurate definition and management of idiopathic sclerosing encapsulating peritonitis". World Journal of Gastroenterology. 21 (2). Baishideng Publishing Group Inc.: 675–687. doi: 10.3748/wjg.v21.i2.675 . ISSN   1007-9327. PMC   4292304 . PMID   25593498.
  49. 1 2 3 Ti, Joanna P.; Al-Aradi, Ali; Conlon, Peter J.; Lee, Michael J.; Morrin, Martina M. (2010). "Imaging Features of Encapsulating Peritoneal Sclerosis in Continuous Ambulatory Peritoneal Dialysis Patients". American Journal of Roentgenology. 195 (1). American Roentgen Ray Society: W50 –W54. doi:10.2214/ajr.09.3175. ISSN   0361-803X. PMID   20566781.
  50. ↑ Stuart, Sam; Stott, David; Goode, Antony; Cash, Charlotte J; Davenport, Andrew (December 22, 2016). "Can radiological assessment of abdominal computerized scans diagnose encapsulating peritoneal sclerosis in long-term peritoneal dialysis patients?". Nephrology. 22 (1). Wiley: 19–24. doi:10.1111/nep.12718. ISSN   1320-5358. PMID   26730546. S2CID   21844894.
  51. ↑ Upponi, S.; Butler, A.J.; Watson, C.J.E.; Shaw, A.S. (2014). "Encapsulating peritoneal sclerosis—Correlation of radiological findings at CT with underlying pathogenesis". Clinical Radiology. 69 (1). Elsevier BV: 103–109. doi:10.1016/j.crad.2013.09.004. ISSN   0009-9260. PMID   24209872.
  52. ↑ Jovani, Manol; Baticci, Fabio; Bonifacio, Cristiana; Omodei, Paolo Dario; Malesci, Alberto (2014). "Abdominal cocoon or idiopathic encapsulating peritoneal sclerosis: Magnetic resonance imaging". Digestive and Liver Disease. 46 (2). Elsevier BV: 192–193. doi:10.1016/j.dld.2013.08.136. ISSN   1590-8658. PMID   24055233.
  53. ↑ Brown, Edwina A.; Bargman, Joanne; van Biesen, Wim; Chang, Ming-Yang; Finkelstein, Frederic O.; Hurst, Helen; Johnson, David W.; Kawanishi, Hideki; Lambie, Mark; de Moraes, Thyago Proença; Morelle, Johann; Woodrow, Graham (2017). "Length of Time on Peritoneal Dialysis and Encapsulating Peritoneal Sclerosis — Position Paper for ISPD: 2017 Update". Peritoneal Dialysis International. 37 (4). SAGE Publications: 362–374. doi: 10.3747/pdi.2017.00018 . hdl: 1854/LU-8529222 . ISSN   0896-8608. PMID   28676507.
  54. ↑ Braun, Niko; Fritz, Peter; Ulmer, Christoph; Latus, Joerg; Kimmel, Martin; Biegger, Dagmar; Ott, German; Reimold, Fabian; Thon, Klaus-Peter; Dippon, Juergen; Segerer, Stephan; Alscher, M. Dominik (November 7, 2012). "Histological Criteria for Encapsulating Peritoneal Sclerosis – A Standardized Approach". PLOS ONE. 7 (11) e48647. Public Library of Science (PLoS). Bibcode:2012PLoSO...748647B. doi: 10.1371/journal.pone.0048647 . ISSN   1932-6203. PMC   3492493 . PMID   23144917.
  55. 1 2 Kawanishi, Hideki; Kawaguchi, Yoshindo; Fukui, Hiroyoshi; Hara, Shigeko; Imada, Akio; Kubo, Hitoshi; Kin, Masao; Nakamoto, Masahiko; Ohira, Seiji; Shoji, Takao (2004). "Encapsulating peritoneal sclerosis in Japan: a prospective, controlled, multicenter study". American Journal of Kidney Diseases. 44 (4): 729–737. doi:10.1016/S0272-6386(04)00953-9. PMID   15384025.
  56. ↑ Garosi, Guido; Paolo, Nicola Di; Sacchi, Giovanni; Gaggiotti, Enzo (February 2005). "Sclerosing peritonitis: a nosological entity". Peritoneal Dialysis International. 25 (3): S110 –S112. doi:10.1177/089686080502503S28. PMID   16048272.
  57. ↑ Freitas, Declan de; Jordaan, Antoinette; Williams, Rosalind; Alderdice, Jane; Curwell, Janet; Hurst, Helen; Hutchison, Alastair; Brenchley, Paul E C; Augustine, Titus; Summers, Angela M (2008). "Nutritional management of patients undergoing surgery following diagnosis with encapsulating peritoneal sclerosis". Peritoneal Dialysis International. 28 (3): 271–276. doi:10.1177/089686080802800314. PMID   18474920. S2CID   40920566.
  58. ↑ Sud, Rahul; Garry, Lorraine; Spicer, Stephen Timothy; Allen, Richard DM; Eris, Josette M; Wyburn, Kate; Verran, Deborah; Cooper, Caroline Louise; Chadban, Steve (March 14, 2014). "A role for everolimus in post-transplant encapsulating peritoneal sclerosis: First case report". Nephrology. 19 (S1). Wiley: 27–30. doi:10.1111/nep.12196. ISSN   1320-5358. PMID   24460661. S2CID   30166094.
  59. ↑ Romagnoli, J.; Pedroso, J.A.; Paola Salerno, M.; Favi, E.; Spagnoletti, G.; Citterio, F. (2014). "Posttransplant Encapsulating Peritoneal Sclerosis, Long-Term Success With Everolimus and Low-Dose CNI: A Case Report". Transplantation Proceedings. 46 (7). Elsevier BV: 2368–2370. doi:10.1016/j.transproceed.2014.07.060. ISSN   0041-1345. PMID   25242790.
  60. ↑ Huddam, Bülent; Başaran, Murat; Koçak, Gülay; Azak, Alper; Yalçın, Funda; Reyhan, Nihan Haberal; Duranay, Murat (July 10, 2015). "The use of mycophenolate mofetil in experimental encapsulating peritoneal sclerosis". International Urology and Nephrology. 47 (8). Springer Science and Business Media LLC: 1423–1428. doi:10.1007/s11255-015-1015-z. ISSN   0301-1623. PMID   26159779. S2CID   205215.
  61. ↑ Bozkurt, Devrim; Bicak, Selahattin; Sipahi, Savas; Taskin, Huseyin; Hur, Ender; Ertilav, Muhittin; Şen, Sait; Duman, Soner (2008). "The Effects of Colchicine on the Progression and Regression of Encapsulating Peritoneal Sclerosis". Peritoneal Dialysis International. 28 (5_suppl). SAGE Publications: 53–57. doi:10.1177/089686080802805s11. ISSN   0896-8608. PMID   19008543.
  62. ↑ Ceri, Mevlut; Unverdi, Selman; Dogan, Mehmet; Unverdi, Hatice; Karaca, Gokhan; Kocak, Gulay; Kurultak, Ilhan; Akbal, Erdem; Can, Murat; Duranay, Murat (April 15, 2012). "Effect of sirolimus on the regression of peritoneal sclerosis in an experimental rat model". International Urology and Nephrology. 44 (3). Springer Science and Business Media LLC: 977–982. doi:10.1007/s11255-012-0167-3. ISSN   0301-1623. PMID   22528580. S2CID   26941363.
  63. ↑ Loureiro, Jesús; Aguilera, Abelardo; Selgas, Rafael; Sandoval, Pilar; Albar-Vizcaíno, Patricia; Pérez-Lozano, María Luisa; Ruiz-Carpio, Vicente; Majano, Pedro L.; Lamas, Santiago; Rodríguez-Pascual, Fernando; Borras-Cuesta, Francisco; Dotor, Javier; López-Cabrera, Manuel (2011). "Blocking TGF-β1 Protects the Peritoneal Membrane from Dialysate-Induced Damage". Journal of the American Society of Nephrology. 22 (9). Ovid Technologies (Wolters Kluwer Health): 1682–1695. doi:10.1681/asn.2010111197. hdl: 10486/668378 . ISSN   1046-6673. PMC   3171939 . PMID   21742730.
  64. ↑ Célicout, Betty; Levard, Hugues; Hay, Jean-Marie; Msika, Simon; Fingerhut, Abe; Pelissier, Edouard; French Associations for Surgical Research, F (1998). "Sclerosing Encapsulating Peritonitis: Early and Late Results of Surgical Management in 32 Cases". Digestive Surgery. 15 (6). S. Karger AG: 697–702. doi:10.1159/000018681. ISSN   0253-4886. PMID   9845640. S2CID   46805116.
  65. ↑ Ulmer, Christoph; Braun, Niko; Rieber, Fabian; Latus, Joerg; Hirschburger, Sandra; Emmel, Jens; Alscher, M. Dominik; Steurer, Wolfgang; Thon, Klaus-Peter (2013). "Efficacy and morbidity of surgical therapy in late-stage encapsulating peritoneal sclerosis". Surgery. 153 (2). Elsevier BV: 219–224. doi:10.1016/j.surg.2012.07.033. ISSN   0039-6060. PMID   22981361.
  66. ↑ Brown, Michaela C.; Simpson, Keith; Kerssens, Jan J.; Mactier, Robert A. (2009). "Encapsulating Peritoneal Sclerosis in the New Millennium". Clinical Journal of the American Society of Nephrology. 4 (7). Ovid Technologies (Wolters Kluwer Health): 1222–1229. doi:10.2215/cjn.01260209. ISSN   1555-9041. PMC   2709523 . PMID   19541815.
  67. ↑ Jagirdar, Rajesh M.; Bozikas, Andreas; Zarogiannis, Sotirios G.; Bartosova, Maria; Schmitt, Claus Peter; Liakopoulos, Vassilios (November 16, 2019). "Encapsulating Peritoneal Sclerosis: Pathophysiology and Current Treatment Options". International Journal of Molecular Sciences. 20 (22). MDPI AG: 5765. doi: 10.3390/ijms20225765 . ISSN   1422-0067. PMC   6887950 . PMID   31744097.
  68. ↑ Lambie, Mark; Teece, Lucy; Johnson, David W; Petrie, Michaela; Mactier, Robert; Solis-Trapala, Ivonne; Belcher, John; Bekker, Hilary L; Wilkie, Martin; Tupling, Ken; Phillips-Darby, Louise; Davies, Simon J (February 28, 2019). "Estimating risk of encapsulating peritoneal sclerosis accounting for the competing risk of death". Nephrology Dialysis Transplantation. 34 (9). Oxford University Press (OUP): 1585–1591. doi:10.1093/ndt/gfz034. ISSN   0931-0509. PMC   6735880 . PMID   30820552.

Further reading

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.